ArticlePCN reports : psychiatry and clinical neurosciences2026
Pre-corticosteroid delusional psychosis and olanzapine-responsive behavioral dyscontrol in autoimmune glial fibrillary acidic protein astrocytopathy: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is an immunotherapy-responsive inflammatory central nervous system disorder. Psychiatric manifestations include delirium, cognitive or behavioral change, apathy, depressive symptoms, and anxiety; however, frank delusional psychosis before corticosteroid exposure is rarely characterized. Timing is critical because corticosteroids can themselves cause psychosis. Case Presentation: A 42-year-old man with no previous psychotic disorder developed a progressive subacute syndrome over several months, beginning with headache and followed by impaired fine motor function, dysarthria, dysphagia, tremor, and cognitive decline. Cerebrospinal fluid (CSF) showed inflammation, and CSF GFAP-immunoglobulin G (IgG) was confirmed by qualitative cell-based and tissue-based assays. Before corticosteroid pulse therapy or oral prednisolone, his family observed a new persecutory delusion that someone was outside the window. Immunotherapy was led by neurologists, and psychiatric symptoms were assessed by psychiatrists through consultation and later psychiatric hospitalization. After corticosteroid therapy, neurological symptoms partially improved, but persecutory ideas, grandiosity, insomnia, irritability, aggression, and escape behavior became prominent. Prednisolone was continued because of the autoimmune neurological disease. Olanzapine was titrated to 15 mg/day. Behavioral dyscontrol improved markedly despite continued prednisolone, and physical restraint was no longer required; however, residual grandiose delusional ideas persisted. Conclusion: This case suggests that delusional psychosis can be an early manifestation of autoimmune GFAP astrocytopathy. Because the first delusion preceded corticosteroid exposure, steroid-induced psychosis was excluded as the mechanism of onset. Olanzapine may stabilize severe behavioral dyscontrol while necessary corticosteroid therapy is maintained, although residual delusions may persist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.